# ROBERT SCOTT (PHARMACY) LIMITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2014 AS MODIFIED BY PART 15, COMPANIES ACT 2006

J.3 NOV 2014

BELFAST



\*J3KK4UGJ\* NI 13/11/2014 COMPANIES HOUSE

#47

### **BALANCE SHEET**

### ROBERT SCOTT (PHARMACY) LIMITED

AT 31 MARCH	NOTE	£	2014 £	£	2013 £
FIXED ASSETS					
Tangible assets	2		104649		104649
CURRENT ASSETS					
Debtors Cash at bank		385 58042		385 101072	
•		58427		101457	
Less: Creditors - Amounts falling due within one year		( 3526)		(· 3379)	
NET CURRENT ASSETS			54901		98078
TOTAL ASSETS LESS CURREN LIABILITIES	<b>IT</b>		÷ (159550) €		202727
Amounts due after one year Provision for charges	3		Sankara e da Barto-e	•	-
TOTAL NET ASSETS			159550		202727
CAPITAL AND RESERVES			:		
CALLED UP SHARE CAPITAL	4		8000		8000
SHARE PREMIUM ACCOUNT	4		46000		46000
PROFIT AND LOSS ACCOUNT REVALUATION RESERVE	5		25550 80000		68727 80000
REVALUATION RESERVE	3			• .	
TOTAL SHAREHOLDERS' FUN	DS		159550	,	202727

<sup>-</sup>Balance Sheet continued on next page -

### **BALANCE SHEET - CONTINUED**

### ROBERT SCOTT (PHARMACY) LIMITED

TI	ha	di	rector	confirm	c that
	110	ш	rector	COMMITTE	S IIIAL

- a) For the year ending 31 March 2014 the company was entitled to exemption under Section 477 of the Companies Act 2006;
- b) No notice has been deposited by members under Section 476 of the Companies Act 2006 calling for an audit in relation to the accounts for the financial year; and
- c) The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 and with respect to accounting records and the preparation of accounts.

The accounts have been prepared in accordance with the special provisions relating to small companies subject to the small companies regime within part 15 of the Companies Act 2006.

SIGNED FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

E. Arma Scott

Mrs E A Scott

DIRECTOR

### NOTES TO THE FINANCIAL STATEMENTS ROBERT SCOTT (PHARMACY) LIMITED

#### 1 ACCOUNTING POLICIES

The following accounting policies have been used consistently in dealing with items which are considered material in relation to the company's financial statements.

### (a) Basis of Accounting

The financial statements are prepared under the historical cost convention as amended for the revaluation of certain tangible assets and in accordance with Financial Reporting Standards for Smaller Entities (effective April 2008).

### (b) Cash Flow

The financial statements do not include a cash flow statement because the company, as a small reporting entity, is exempt from the requirement to prepare such a statement under Financial Reporting Standard 1 'Cash flow statements'.

### (c) Turnover

Turnover comprises the invoiced value of goods and services (excluding VAT) sold to customers, less trade allowances and discounts.

Turnover is attributable to the one principal activity of the company carried on within the United Kingdom and Europe.

### (d) Tangible fixed assets and depreciation

Building is included at its revalued amount and is not depreciated. The company continues to retain its policy of revaluation as permitted in certain circumstances by FRS 15.

### (e) Deferred taxation

Deferred taxation is provided on the liability method in respect of the differences between the net book value and the tax written down value of tangible fixed assets qualifying for capital allowances.

### (f) Dividends

In accordance with FRS 21 proposed dividends are accounted for in the financial year in which they are paid.

### NOTES TO THE FINANCIAL STATEMENTS - CONTINUED ROBERT SCOTT (PHARMACY) LIMITED

#### 2 FIXED ASSETS

LO	NG LEASEHOLD	
	BUILDING £	TOTAL £
COST	r.	*
At 31 March 2013 and at 31 March 2014	104649	104649
DEPRECIATION		
At 31 March 2013 Charge for the year	- -	-
At 31 March 2014	-	<del></del>
NET BOOK VALUE		<u></u>
At 31 March 2014	104649	104649

### Leasehold Buildings

Business premises at 62 Stranmillis Road, Belfast are stated in the financial statements at their aggregate open market value, on an existing use basis during an earlier year, and after the completion of improvement expenditure. The director is not a qualified property valuer.

The revaluation of the building gave rise to a revaluation surplus of £80000 which has been transferred to revaluation reserve - Note 5.

### **Accounting Policy**

The company continues to retain its policy of revaluation as permitted in certain circumstances by the Accounting Standard of Tangible Fixed Assets FRS15.

The FRS permits exclusion of properties on which the accrued charge and accumulated depreciation charge are immaterial as a result of both long estimated useful lives and high residual values.

The director considers these conditions exist in respect of its property and accordingly it has not been depreciated. The carrying value above is retained subject to the requirement to test this asset periodically for impairment of value in accordance with FRS11.

## NOTES TO THE FINANCIAL STATEMENTS - CONTINUED ROBERT SCOTT (PHARMACY) LIMITED

### 3 PROVISIONS FOR LIABILITIES AND CHARGES

**Deferred Taxation** 

A provision for deferred taxation is not required at the balance sheet date.

### 4 CALLED UP SHARE CAPITAL AND SHARE PREMIUM

	Authorised		Allotted and fully paid	
	2014 £	2013 £	2014 £	2013 £
Ordinary shares of £1 each	15000	15000	. 8000	8000

At the balance sheet date directors interests in the issued share capital of the company were as follows:

	Nominal value	
	2014	2013
	£	£
		•
Mrs Anna Scott	8000	8000
		<del></del>
SHARE PREMIUM		
	2014	2013
	£	£
Premium arising on 1997 share issue	46000 .	46000
		•

# NOTES TO THE FINANCIAL STATEMENTS - CONTINUED ROBERT SCOTT (PHARMACY) LIMITED

### 5 REVALUATION RESERVE

In respect of tangible fixed assets (Note 2)	2014 £	2013 £
Reserve balance at 31 March 2013 and at 31 March 2014	80000	80000

### 6. CONTROLLING INTERESTS

Street Carlo Siller

no concepto contra

Mrs Scott is the controlling shareholder by virtue of her shareholding in the company.

The first and property in the

### 7 APPROVAL OF FINANCIAL STATEMENTS

COMMISSION OF STATE O

nation from the first transfer of the control of th

These financial statements were approved by the director on 11 October 2014